BioSpace News Archive

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will present preclinical data on novel XmAb® CD28 bispecific antibody programs at the American Association for Cancer Research (AACR) Annual Meeting, being held April 14-19, 2023 at the Orange County Convention Center in Orlando, Florida.

MedMira Inc. provides an update on its progress to achieve regulatory approval in Canada for its Reveal® TP antibody test.

Nurix Therapeutics, Inc. announced that preclinical data from its targeted protein degradation programs, NX-2127 and NX-5948, will be presented at the American Association for Cancer Research 2023 Annual Meeting, which is being held from April 14-19, 2023, in Orlando, FL.

Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced it will be presenting two late-breaking abstracts during the American Association for Cancer Research (AACR) Annual Meeting to be held April 14-19, 2023 at the Orange County Convention Center in Orlando, Florida.

Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS) today announced that preclinical data exploring purposeful armoring of CAR T-cells to enhance efficacy of MUC1 CAR T-cells in targeting triple-negative breast cancer, will be presented at the American Association of Cancer Research (AACR) Annual Meeting, to be held in Orlando, Florida on April 14-19, 2023.

Travere Therapeutics, Inc. announced that on March 10, 2023, the Compensation Committee of its Board of Directors granted inducement equity grants to four new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 17,250 shares of its common stock.

Immune-Onc Therapeutics, Inc. (“Immune-Onc”) today announced that Phase 1 dose escalation data for IO-108, a novel myeloid checkpoint inhibitor targeting Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2, also known as ILT4) is selected for oral presentation at the American Association for Cancer Research (AACR) Annual Meeting being held April 14 - 19, 2023 in Orlando, Florida.

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that two abstracts have been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, to be held in Orlando from April 14-19, 2023.

SkinCure Oncology today announced the successful Image-Guided SRT treatment of the 50,000th patient in the United States.

Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, launched first in human clinical trial of its iron homeostasis regulating macromolecular drug 9MW3011.